Bristol-Myers Squibb Company (BMY) Upgraded to Buy at Argus Research

Market Context

Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $63.63 with a market capitalization of $104.2B. The stock has gained 38.5% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Argus Research's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bristol-Myers Squibb Company

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 05, 2026	Argus Research	Buy	N/A
Aug 03, 2026	Citigroup	Neutral	N/A
Jul 31, 2026	Wells Fargo	Equal-Weight	N/A
Jul 31, 2026	Truist Securities	Buy	N/A
Jul 31, 2026	Guggenheim	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BMY Stock Page